(MENAFN- Investor Brand Network) Lexaria is a biotechnology company focused on licensing its proprietary DehydraTECH(TM) technology The DehydraTECH technology has been proven to increase the bioavailability, speed of onset and brain absorption of APIs, and improve customer experiences by masking unwanted tastes Lexaria has 25 patents granted worldwide and is pursuing numerous other pending patent applications The company operates several subsidiary companies to focus on different commercial opportunities
Ever since acquiring its first intellectual property (“IP”) that subsequently formed the basis of its first two patent application filings in 2014, biotechnology company
lexaria bioscience (nasdaq: lexx)
has grown the number of patents granted and patent applications exponentially, with 25 patents granted worldwide as of April 2022. The latest patent, the 10th granted in the United States, represents the first-ever patent for the use of DehydraTECH(TM) drug delivery technology in the enhanced delivery of antiviral drugs. Described by CEO Chris Bunka as“another validation of the versatility of our DehydraTECH drug technology,” the award of the IP protection marks a key step toward the ultimate monetization of DehydraTECH, according to an April 21 news release ( ).
This monetization, Lexaria's annual report (Form 10-K filing) for the fiscal year ended August 2021 notes ( ), will be realized through the company's focus on R&D and subsequent strategic...
read more>>
NOTE TO INVESTORS:
The latest news and updates relating to LEXX are available in the company's newsroom at
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing
cbdnewsbreaks
crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
Do you have questions or are you interested in working with CNW?
ask our editor
CBDWire (CBDW)
Denver, Colorado
303.498.7722 Office
CBDWire is part of the
investorbrandnetwork .
MENAFN09062023000224011066ID1106416202
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.